Results 1 to 10 of about 26,368 (251)

Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A). [PDF]

BMC Cancer
Sano Y, Kajikawa R, Mizusawa J, Ioka T, Ozaka M, Nakamura S, Ito Y, Furuse J, Kobayashi S, Fukuda H, Okusaka T, Ikeda M, Miwa H, Sasahira N, Nagashima F, Ohkawa K, Yamazaki K, Kanai M, Yamashita T, Hara K, Takayama Y, Komatsu Y, Fujimori N, Hama N, Kamata K, Hisano T, Shimizu S, Tobimatsu K, Maeda S, Ueno M.   +29 more
europepmc   +1 more source

Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. [PDF]

Oncologist
Procaccio L, Giordano G, Nichetti F, Milella M, Pretta A, Iacono D, Niger M, Casalino S, Vivaldi C, De Vita F, Pusceddu V, Landriscina M, Di Paolo G, Sperotto S, Masucci M, Tortora G, Bianco R, Vasile E, Zaniboni A, Miceli CC, Ongaro E, Giommoni E, Tinè G, Barsotti G, Marchesi S, Di Marco M, Ortolani S, Aprile G, Scartozzi M, Bergamo F, Melisi D, Lonardi S.   +31 more
europepmc   +1 more source

Nab-paclitaxel plus bevacizumab for patients with metastatic extrapulmonary neuroendocrine carcinoma: a phase 2 single-arm study. [PDF]

EClinicalMedicine
Zhang P, Li S, Jia R, Hao J, Chen C, Gan S, Li J, Shen L, Lu M.   +8 more
europepmc   +1 more source

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial. [PDF]

ESMO Open
Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van Cutsem E, Bekaii-Saab T, Zhang L, Li J, Chen H, Maxwell F, Wainberg ZA, Melisi D.   +19 more
europepmc   +1 more source

Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer. [PDF]

Clin Cancer Res
Grierson PM, Wolf C, Suresh R, Wang-Gillam A, Tan BR, Ratner L, Oppelt P, Aranha O, Frith A, Pedersen KS, Spann J, Boice N, Brown A, Baer JM, Butka EG, Ahmad F, Xu Y, Liu J, DeNardo DG, Lim KH.   +19 more
europepmc   +1 more source

Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. [PDF]

J Immunother Cancer
O'Reilly EM, Cabanski CR, Lyman JP, Wainberg ZA, Fisher GA, Wolff RA, Ko AH, O'Hara MH, Spencer CN, Yu JX, Da Silva DM, Padrón LJ, Arnott J, Fairchild J, Moore JS, Peng B, Hoos WA, O'Donnell-Tormey J, Boffo S, Dugan U, Kimmelman AC, Amaravadi RK, Vonderheide RH.   +22 more
europepmc   +1 more source

Factors associated with taxane-associated acute pain syndrome in pancreatic cancer patients receiving gemcitabine and nab-paclitaxel. [PDF]

Discov Oncol
Saito Y, Takekuma Y, Komatsu Y, Sugawara M.   +3 more
europepmc   +1 more source

Response to Corcept's retraction request on manuscript of "Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study". [PDF]

J Gynecol Oncol
Xu Q.
europepmc   +1 more source

-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial [PDF]

core   +1 more source

Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial. [PDF]

Nat Commun
Waks AG, Fu J, Chu X, Binboga Kurt B, Li T, Kuntz TM, Shen Y, Yang D, Meli K, Reardon B, Park J, Partridge A, Abravanel D, Jeselsohn R, Wrabel E, Alberti J, DiLullo M, Chen S, Mohammed-Abreu A, Sun X, Balko JM, Kleijn M, Audeh W, Morgan XC, Krop IE, Tayob N, Van Allen EM, Mittendorf EA, Tolaney SM.   +28 more
europepmc   +1 more source